[go: up one dir, main page]

HK1251572A1 - 作為ddr1抑制劑的三氮雜-螺癸酮類化合物 - Google Patents

作為ddr1抑制劑的三氮雜-螺癸酮類化合物

Info

Publication number
HK1251572A1
HK1251572A1 HK18111175.4A HK18111175A HK1251572A1 HK 1251572 A1 HK1251572 A1 HK 1251572A1 HK 18111175 A HK18111175 A HK 18111175A HK 1251572 A1 HK1251572 A1 HK 1251572A1
Authority
HK
Hong Kong
Prior art keywords
spirodecanones
triaza
ddr1 inhibitors
ddr1
inhibitors
Prior art date
Application number
HK18111175.4A
Other languages
English (en)
Inventor
貝恩德‧布埃特爾曼
布埃倫特‧科切爾
貝恩德‧庫恩
馬爾科‧普魯諾托
漢斯‧里斯特
馬丁‧里特爾
馬庫斯‧魯道夫
亞歷山大‧李‧薩茨
Original Assignee
豪夫邁．羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁．羅氏有限公司 filed Critical 豪夫邁．羅氏有限公司
Publication of HK1251572A1 publication Critical patent/HK1251572A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK18111175.4A 2015-07-03 2018-08-30 作為ddr1抑制劑的三氮雜-螺癸酮類化合物 HK1251572A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175259 2015-07-03

Publications (1)

Publication Number Publication Date
HK1251572A1 true HK1251572A1 (zh) 2019-02-01

Family

ID=53510782

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111175.4A HK1251572A1 (zh) 2015-07-03 2018-08-30 作為ddr1抑制劑的三氮雜-螺癸酮類化合物

Country Status (6)

Country Link
US (2) US10239876B2 (zh)
EP (1) EP3317279B1 (zh)
JP (1) JP7002335B2 (zh)
CN (1) CN107849044B (zh)
HK (1) HK1251572A1 (zh)
WO (1) WO2017005583A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4177800B2 (ja) * 2003-12-25 2008-11-05 日精樹脂工業株式会社 型締装置の金型保護方法
JP6990657B2 (ja) 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
JP2023528310A (ja) 2020-05-25 2023-07-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｄｄｒ阻害物質としてのベンジルアミン誘導体
US20240199635A1 (en) * 2021-03-26 2024-06-20 Chiesi Farmaceutici S.P.A. Tetrahydrothieno pyridine derivatives as ddrs inhibitors
WO2024251855A1 (en) 2023-06-07 2024-12-12 Chiesi Farmaceutici S.P.A. Heteroaryl derivatives as ddrs inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3839342A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro(4.5)decanes
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
CN1081635C (zh) * 1993-05-06 2002-03-27 默里尔药物公司 取代的吡咯烷 －3－基－烷基－哌啶
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
EP0921125B1 (en) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
EP1087770A4 (en) * 1998-06-15 2001-11-14 Merck & Co Inc INHIBITORS OF PRENYL PROTEIN TRANSFERASE
MXPA01002173A (es) * 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2005231995A (ja) * 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
ATE337318T1 (de) * 2000-09-25 2006-09-15 Toray Industries Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
US6777421B2 (en) * 2001-04-10 2004-08-17 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CN101273046B (zh) * 2005-09-28 2011-05-25 弗·哈夫曼-拉罗切有限公司 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
WO2010027567A2 (en) * 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
EP2421532A4 (en) * 2008-10-02 2012-07-04 Univ Johns Hopkins SPIPERON DERIVATIVES AND METHOD FOR THE TREATMENT OF ILLNESSES
AU2011268073B2 (en) * 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use

Also Published As

Publication number Publication date
WO2017005583A1 (en) 2017-01-12
CN107849044B (zh) 2021-06-25
JP2018519317A (ja) 2018-07-19
US20180148450A1 (en) 2018-05-31
US10435407B2 (en) 2019-10-08
JP7002335B2 (ja) 2022-01-20
US20190169189A1 (en) 2019-06-06
CN107849044A (zh) 2018-03-27
EP3317279B1 (en) 2021-01-27
US10239876B2 (en) 2019-03-26
EP3317279A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1249097A1 (zh) 作為pde1抑制劑的咪唑並三嗪酮
GB201421083D0 (en) Enzyme inhibitors
IL251932B (en) Benzylpropargyl ether as nitrification inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HK1252098B (zh) 作為pde1抑制劑的咪唑並吡嗪酮
GB201513481D0 (en) Inhibitor compounds
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201505658D0 (en) Inhibitor compounds
HK1251572A1 (zh) 作為ddr1抑制劑的三氮雜-螺癸酮類化合物
GB201612860D0 (en) Inhibitors
GB201501004D0 (en) Inhibitors
HK1258415A1 (zh) 作為致癌基因 erg 的抑制劑的偶氮苯酚
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
HK1244790A1 (zh) Bace1抑制劑
PT3322724T (pt) Inibidores da il-26
GB201520949D0 (en) Inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201522453D0 (en) Inhibitor compounds
GB201418154D0 (en) Inhibitors